What you should know:
– Nuclearleader in space biology and AIAnd GoPath Diagnosticsa leading provider of digital pathology and molecular diagnostics, today announced a strategic collaboration.
– The partnership aims to revolutionize clinical trials, diagnostics and research in oncology and immunology by combining their strengths in AI and real-world data.
Unlocking the power of AI spatial biomarkers
Nucleai specializes in “AI spatial biomarkers”. This technology analyzes tissue samples to understand the complex communication and interaction between cells. By deciphering these “cellular conversations,” Nucleai’s AI can predict how patients will respond to specific treatments.
GoPath’s expertise in real-world data and diagnostics
GoPath Diagnostics brings extensive experience in digital pathology and molecular diagnostics. They offer a full range of services, including:
- Digital pathology: GoPath offers advanced digital tools for analyzing tissue samples.
- Molecular diagnosis: Their services include cutting-edge molecular testing for a deeper understanding of diseases.
- Real world data: GoPath has a rich dataset of real-world patient information.
AI-powered digital pathology solutions
By combining these strengths, Nucleai and GoPath aim to:
- Develop AI-based digital pathology solutions: Nucleai’s AI will be integrated into GoPath’s digital pathology platform, creating a powerful solution for clinical trials and diagnostics.
- Centralized and secure environment: AI analysis will take place in a secure environment meeting the highest regulatory standards. This ensures data confidentiality and compliance.
- Actionable insights for clinicians: AI will provide clinicians with valuable insights to support patient care decisions throughout the treatment journey.
- Support for biopharmaceutical partners: The collaboration will streamline research for pharmaceutical companies by providing access to real-world data, AI capabilities and comprehensive laboratory services.
Focus on actionable results
The partnership will initially focus on developing AI-based pathology analysis tools that provide practical and clinically relevant information for multiple clinical trials and research studies in oncology and immunology. This includes areas like prostate cancer and inflammatory bowel disease.
